This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drugdevelopment world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.
Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drugdevelopers may need to reassess their therapeutic strategies. This has led drugdevelopers to unintentionally limit their potential within chosen therapeutic spaces.
Drugdevelopment is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 5] The company announced in July 2024 that the FDA had accepted a new drug application for suzetrigine. [11]
Smallmolecule GLP1s? Whether trial design, execution, or otherwise, drugdevelopment even where there is precedent is a challenging road and should not be taken for granted. Whether it’s smallmolecules to target the incretins (GLP1R ± GIPR), targeting well-validated signaling nodes in I&I (e.g.,
By complementing traditional analytical methods, it provides a more accurate representation of drug behaviour to support translational and pre-clinical studies. This article explores the principles, applications and future potential of MSI in drugdevelopment. Drug Discovery Today 2025, 30 (1), 104275.
Let Us Guide You Through the Process blussier Mon, 02/10/2025 - 17:54 HTML Let Us Guide You Through the Process Altasciences' experts streamline the IND/CTA application process by designing your regulatory strategy and thoroughly planning and completing your required preclinical studies.
Optimizing Formulation Strategies for Poorly Soluble Compounds: Insights into Bioavailability Enhancement and Accelerated Development dwunderlin Fri, 01/03/2025 - 15:54 Wed, 02/19/2025 - 11:00 Resource Type Webinar Feng Zhang, Ph.D. On Demand Start Date Wed, 02/19/2025 - 12:00 Hong Li, Ph.D.
On July 31, 2024, the US Food and Drug Administration (FDA) announced Fiscal Year 2025 (FY2025) Prescription Drug User Fee Amendments of 2022 (PDUFA VII) fee rates for the review of human drug and biological product applications along with prescription drug program fees. i] United States Federal Register.
2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] 4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] Drug Discovery. nM vs. 24.0 PMID 34826432.
Case Study: How Altasciences Overcame Pharmacological Challenges in a GLP-1 IND-Enabling Study pmjackson Thu, 04/24/2025 - 21:43 For emerging therapies with pronounced pharmacological effects, thoughtful study design is critical to ensuring reliable and interpretable data. This blog was originally published in April 2025.
By 2025, Dupixent is expected to generate an additional 11 new regulatory submissions across indications and age groups. These drugdevelopment programs include our acceleration of priority asset amlitelimab, an anti-OX40L antibody that aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T cells.
Published June 23, 2025 Delilah Alvarado Staff Reporter post share post print email license A micrograph image of influenza A virus. The drug, an antiviral that combines a smallmolecule with a protein fragment, met its main and secondary goals in a Phase 2b trial. Influenza A virus" [Micrograph]. Retrieved from Flickr.
Altasciences Receives 2025 CDMO Leadership Award in SmallMolecule Dosage Form Category pmjackson Thu, 03/27/2025 - 19:42 Laval, Qubec, March 27, 2025 Altasciences , a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the SmallMolecule Dosage FormNorth America category.
Drug Target Review had the pleasure of attending SLAS Europe 2025 in Hamburg and what we saw was no mere showcase of cutting-edge tools, but a clear snapshot of where drug discovery is heading. So what really stood out at SLAS 2025? These are things the platform now enables. We dont just generate data for the sake of it.
Drugdevelopment is hampered by high costs, long timelines and a low probability of success and complex therapies exacerbate these challenges. Even excluding repositioned drugs, which could benefit from pre-existing toxicology and clinical data, a significant increase in PoS is still observed. This is an AI-generated image.
At the risk of diving into the scientific weeds, what follows is an attempt to highlight the importance of these findings and their implications for drugdevelopment in muscular dystrophy. As such, the DGC and its underlying biophysical and mechanical properties have long been of high interest for academics and drugdevelopers alike.
2 Liver CIVMs offer several benefits over conventional in vitro systems including prolonged functional activity, enhanced expression of various drug-metabolising enzymes and transporters, and improved cell-cell and cell-ECM (extracellular matrix) interactions. link] (accessed March 20, 2025). [13] 2024 [cited 2025 Apr 16].
While small-moleculedrugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. Peptide-Based Drugs Sessile organisms, whether a sponge, coral, plant, or mushroom, are often quite literally between a rock and a hard place.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content